NASDAQ:CFRX - ContraFect Stock Price, Forecast & News

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

ContraFect Corp (NASDAQ:CFRX) issued its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.01. View ContraFect's Earnings History.

ContraFect is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for ContraFect.

2 brokerages have issued twelve-month target prices for ContraFect's stock. Their forecasts range from $1.50 to $2.00. On average, they expect ContraFect's stock price to reach $1.75 in the next twelve months. This suggests a possible upside of 68.3% from the stock's current price. View Analyst Price Targets for ContraFect.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ContraFect.

News stories about CFRX stock have been trending very negative on Friday, InfoTrie reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ContraFect earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for ContraFect.

ContraFect saw a increase in short interest during the month of December. As of December 13th, there was short interest totalling 341,900 shares, an increase of 338.3% from the November 28th total of 78,000 shares. Based on an average daily volume of 714,900 shares, the short-interest ratio is presently 0.5 days. Currently, 0.5% of the company's shares are short sold. View ContraFect's Current Options Chain.

Some companies that are related to ContraFect include Cara Therapeutics (CARA), AC Immune (ACIU), TherapeuticsMD (TXMD), Axovant Sciences (AXON), Vectura Group (VEGPF), Emisphere Technologies (EMIS), Prothena (PRTA), Crinetics Pharmaceuticals (CRNX), Kura Oncology (KURA), Morphic (MORF), MacroGenics (MGNX), Akero Therapeutics (AKRO), Kadmon (KDMN), BioDelivery Sciences International (BDSI) and Viking Therapeutics (VKTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Catalyst Pharmaceuticals (CPRX), Antares Pharma (ATRS), Edge Therapeutics (EDGE), Synergy Pharmaceuticals (SGYP), Nabriva Therapeutics (NBRV), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO) and Portola Pharmaceuticals (PTLA).

Shares of CFRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CFRX stock can currently be purchased for approximately $1.04.

ContraFect has a market capitalization of $159.45 million. The biotechnology company earns $-37,680,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. ContraFect employs 20 workers across the globe.View Additional Information About ContraFect.

The official website for ContraFect is http://www.contrafect.com/.

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The biotechnology company can be reached via phone at 914-207-2300 or via email at [email protected]